Spinal chloroprocaine versus bupivacaine without opioid adjuvant for transvaginal cervical cerclage placement: a pragmatic retrospective cohort study (2018–2023)
Authors' conclusion
Intrathecal chloroprocaine dosing at 60 mg could substantially reduce exposure to IV opioid exposure without reducing the advantage of reduced time to void and discharge from the PACU.
Study context
- Population
- Patients undergoing transvaginal cervical cerclage under spinal anaesthesia
- Participants
- 137 vs 67
- Exposure
- Chloroprocaine vs Bupivacaine
- Chloroprocainen = 137
- Bupivacainen = 67reference
- Outcome
- Adequacy of the primary neuraxial anaesthesia
Methodological detailspragmatic
- Pragmatic
Main finding
As reported in the abstract
Adequate primary neuraxial anaesthesia
Observational data: associations, not effects.
Further findings
Estimated ED90 (isotonic regression)
IV opioid supplementation
- Lower in chloroprocaine ≥ED90 vs <ED90, but not between chloroprocaine and bupivacaine
Time to void and to recovery room discharge
- Shorter with both <ED90 and ≥ED90 chloroprocaine vs bupivacaine
- Chloroprocaine doses above the ED90 did not prolong time to void or recovery room discharge
Original publication
Spinal chloroprocaine versus bupivacaine without opioid adjuvant for transvaginal cervical cerclage placement: a pragmatic retrospective cohort study (2018–2023). Int J Obstet Anesth. Published 3 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →